Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 6/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949517 | 0.86 | S1PR1 (0.62) | FAAHS1PR1S1PR3 | |
| SCHEMBL4948244 | 0.82 | TSHR (0.59) | — | |
| SCHEMBL14521763 | 0.82 | THRB (0.61) | NR1H4THRBFAAHSMPD1S1PR1 | |
| SCHEMBL9858310 | 0.82 | NR1H4 (0.68) | NR1H4THRBFAAHSMPD1PLA2G4B | |
| SCHEMBL4950894 | 0.80 | PTPN1 (0.53) | — | |
| Trifluoroacetic Acid SCHEMBL5666468 | 0.79 | S1PR1 (0.53) | NR1H4THRBS1PR1S1PR3 | |
| Trifluoroacetic Acid SCHEMBL20570014 | 0.79 | S1PR1 (0.53) | NR1H4THRBS1PR1S1PR3 | |
| SCHEMBL14544616 | 0.78 | THRB (0.65) | NR1H4THRBFAAHSMPD1 | |
| SCHEMBL2095695 | 0.77 | FAAH (0.65) | NR1H4THRBFAAHSMPD1 | |
| SCHEMBL9769453 | 0.77 | THRB (0.67) | NR1H4THRBFAAHSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D | 2005-11-24 | — | — | US | disclosed |
| US-6875757-B2 | For therapy of cancer, enhancing cell proliferation, and wound | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-05 | — | — | US | disclosed |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | NR1H4 336/4885THRB 1112/4885FAAH 141/4885 |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | NR1H4 336/4885THRB 1112/4885FAAH 141/4885 |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR5 | NR1H4 282/4885THRB 1581/4885FAAH 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.